Pfizer Inc. $PFE Stock: Oppenheimer & Co. Inc. Trims Stake

Oppenheimer & Co. Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 3.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 781,802 shares of the biopharmaceutical company’s stock after selling 28,168 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Pfizer were worth $22,297,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC grew its stake in Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 509 shares during the last quarter. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the last quarter. Keb Asset Management LLC purchased a new stake in Pfizer in the second quarter valued at about $26,000. Field & Main Bank acquired a new stake in Pfizer in the second quarter worth about $27,000. Finally, Global Trust Asset Management LLC boosted its holdings in Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 650 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.8%

Pfizer stock opened at $29.80 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The business’s 50-day simple moving average is $28.30 and its two-hundred day simple moving average is $26.67. The company has a market cap of $169.82 billion, a PE ratio of 39.20, a PEG ratio of 2.04 and a beta of 0.32. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $30.44.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company earned $0.78 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded approval of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer whose tumors have homologous recombination repair (HRR) gene mutations, including BRCA and non-BRCA mutations. Moving the treatment into an earlier stage of metastatic disease could enlarge the addressable patient population and support future sales growth. Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
• Positive Sentiment: Pfizer also reported Phase 2 results across serotypes for its 25-valent pneumococcal conjugate vaccine candidate, 25vPnC. The update adds visibility to the company’s vaccine pipeline, though the available report does not provide enough detail to assess the results’ commercial significance. Pfizer announces results across serotypes in Phase 2 study of 25vPnC
• Neutral Sentiment: Pfizer’s shares have gained about 29.7% over the past year and are near their 52-week high, prompting discussion over whether the valuation is ahead of the company’s earnings growth. Investors may require further pipeline or operating improvements to justify additional gains. Pfizer Stock Looks Above Fair Value As 30% Run Continues
• Neutral Sentiment: Pfizer was relatively resilient while Moderna and BioNTech declined amid disappointment over cancer-vaccine trial data. The comparison may offer some support for PFE, but it does not directly change Pfizer’s fundamentals. Moderna Tumbles as Cancer Vaccine Selloff Deepens
• Negative Sentiment: Broader healthcare stocks traded lower, creating sector-level pressure on Pfizer. Separately, an experimental Pfizer lung-cancer drug showed a survival benefit in some patients despite a failed trial, leaving its development outlook uncertain rather than providing a clear catalyst. Healthcare Stocks Softer Monday

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PFE shares. HSBC boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. JPMorgan Chase & Co. lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Cantor Fitzgerald lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.72.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.